Literature DB >> 20822666

Quantification of rimonabant (SR 141716A) in monkey plasma using HPLC with UV detection.

Martin A Javors1, Jesus J Sanchez, Lance R McMahon.   

Abstract

Using an isocratic high-performance liquid chromatography (HPLC) system and UV detection, a simple and precise analytical procedure was developed to quantify levels of the CB(1) receptor antagonist rimonabant in the plasma of rhesus monkeys. Rimonabant was extracted from plasma samples into 5% isopropanol in hexane. After separation, the isopropanol-hexane fractions were dried to residue, redissolved in mobile phase, and then injected into the HPLC. The HPLC system included an acetonitrile-phosphate buffer (62:38, v/v) mobile phase (pH 6.7), flow rate of 1.5 mL/min, C(18) column (4.6 mm i.d. x 150 mm length, 5 microm), and UV detection at 280 nm. Retention times for rimonabant and doxepin (internal standard) were 9.9 and 2.4 min, respectively. The regression of the spiked calibrator curve was linear from 60 to 4000 ng/mL (r(2) = 0.996). The lower limit of quantification was 60 ng/mL, and recovery was 83.6%. Rimonabant was stable in stock solutions and monkey plasma across a range of temperatures and concentrations. To demonstrate utility, plasma rimonabant was measured in six rhesus monkeys at 60 and 240 min after intramuscular administration of 1 mg/kg rimonabant. Rimonabant levels ranged from 175 to 1290 ng/mL. The analytical assay described here provides a simple and accurate procedure for multiple within-subject measurements of the CB(1) antagonist rimonabant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20822666      PMCID: PMC3148655          DOI: 10.1093/chromsci/48.6.491

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  11 in total

Review 1.  Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.

Authors:  P M Beardsley; B F Thomas
Journal:  Behav Pharmacol       Date:  2005-09       Impact factor: 2.293

2.  Fused-core silica column high-performance liquid chromatography/tandem mass spectrometric determination of rimonabant in mouse plasma.

Authors:  Yunsheng Hsieh; Christine J G Duncan; Jean-Marc Brisson
Journal:  Anal Chem       Date:  2007-07-03       Impact factor: 6.986

3.  Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; R Alonso; D Shire; C Congy; P Soubrié; J C Brelière; G Le Fur
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

4.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

5.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

Authors:  M A Huestis; D A Gorelick; S J Heishman; K L Preston; R A Nelson; E T Moolchan; R A Frank
Journal:  Arch Gen Psychiatry       Date:  2001-04

6.  (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.

Authors:  T U Järbe; R J Lamb; S Lin; A Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

7.  Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.

Authors:  Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2006-09-05       Impact factor: 4.530

8.  Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys.

Authors:  G Tanda; P Munzar; S R Goldberg
Journal:  Nat Neurosci       Date:  2000-11       Impact factor: 24.884

9.  Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry.

Authors:  Melissa McCulloch; Xiang Zhou; Yan Xu; Steve Brunell; Linda Spear
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-01-18       Impact factor: 3.205

10.  Changes in relative potency among positive GABA(A) receptor modulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeys.

Authors:  Lance R McMahon; Martin A Javors; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2007-01-24       Impact factor: 4.415

View more
  1 in total

1.  Purity of synthetic cannabinoids sold online for recreational use.

Authors:  Brett C Ginsburg; Lance R McMahon; Jesus J Sanchez; Martin A Javors
Journal:  J Anal Toxicol       Date:  2012 Jan-Feb       Impact factor: 3.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.